Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2005

View Archived Issues

GTx receives response on SPA for Acapodene for prevention of prostate cancer

Novavax and Wave Biotech to collaborate on production processes

Quarterly activities at Medivir

In vivo efficacy of novel p38alpha MAP kinase inhibitors from BMS

A-761: Novel MCHR1 antagonist with in vivo efficacy and cardiovascular safety

Novel selective adenosine A2A receptor antagonist with anticataleptic activity in vivo

Adjuvant trastuzumab increases survival in early-stage breast cancer

Trans NV-04 reported to reduce cardiovascular risk in overweight subjects

Promising effects of MC-4232 in patients with diabetic hypertension

Phase II data on the benefits of once-daily SPD-476 in ulcerative colitis

Rosiglitazone improves treatment satisfaction in elderly patients with type 2 diabetes

LEO Pharma and Warner Chilcott expand U.S. dermatology cooperation

Myozyme studied for late-onset Pompe disease

Cyclacel and Genzyme sign agreement for CDK inhibitors for renal disease

Huntsman Cancer Institute funded to study Curacyte's PHP

Keppra meets primary endpoint in phase III monotherapy epilepsy study

Dendreon plans Provenge BLA filing

Aplaviroc studies in treatment-naive HIV patients halted over liver toxicity

Macugen recommended for approval in Europe

New therapeutics for cancer disclosed in recent patents

Adartrel receives positive opinion in Europe for restless legs syndrome

Shionogi launches antibiotic Finibax in Japan

Novel immunomodulating agents revealed in patents

Once-monthly Bonviva approved in E.U. for postmenopausal osteoporosis

Clinical evidence supports the use of duloxetine for DPNP

Pranlukast induces neuroprotective effects in a model of cerebral ischemia

New data on the effects of DiaPep277 in patients with type 1 diabetes

Update on the effects of rubitecan in advanced NSCLC

Final phase I data on OGX-011 in prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...